| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Asengeprast | SHP-627; FT-011; FT-11 | Phase 2 Clinical | Fibrotech Therapeutics Pty Ltd, University Of Melbourne | Scleroderma, Diffuse; Scleroderma, Systemic | Details |
| Recombinant Human Platelet-derived Growth Factor B(Lynch Regenerative Medicine) | rhPDGF-BB | Phase 2 Clinical | Lynch Regenerative Medicine LLC | Rectal Fistula | Details |
| REGN-13335 | REGN13335; REGN-13335 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Pulmonary Arterial Hypertension | Details |
| HL-217 | HL-217; KR-31831 | Phase 1 Clinical | Korea Research Institute Of Chemical Technology | Macular Degeneration | Details |